FDA Grants Breakthrough Designation to Multi-Cancer Blood Test

The News:

The FDA has granted Breakthrough Device Designation to SPOT-MAS 10, a multi-omic blood test designed to detect cancer-associated signals across 10 different types, including lung, liver, and breast cancer.

Why it Matters:

Unlike traditional tissue biopsies, this non-invasive test utilizes advanced machine learning to analyze cellfree DNA methylation signatures. It marks a fundamental paradigm shift toward early-detection screening for asymptomatic populations, potentially discovering aggressive, “silent” malignancies before symptoms manifest.